Transformation  ||| S:0 E:15 ||| NN
of  ||| S:15 E:18 ||| IN
primary  ||| S:18 E:26 ||| JJ
human  ||| S:26 E:32 ||| JJ
hepatocytes  ||| S:32 E:44 ||| NN
in  ||| S:44 E:47 ||| IN
hepatocellular  ||| S:47 E:62 ||| FW
carcinoma  ||| S:62 E:72 ||| FW
Hepatocellular  ||| S:72 E:87 ||| FW
carcinoma  ||| S:87 E:97 ||| FW
( ||| S:97 E:98 ||| -LRB-
HCC ||| S:98 E:101 ||| NNP
)  ||| S:101 E:103 ||| -RRB-
is  ||| S:103 E:106 ||| VBZ
the  ||| S:106 E:110 ||| DT
most  ||| S:110 E:115 ||| RBS
common  ||| S:115 E:122 ||| JJ
primary  ||| S:122 E:130 ||| JJ
liver  ||| S:130 E:136 ||| NN
cancer ||| S:136 E:142 ||| NN
.  ||| S:142 E:144 ||| .
Currently ||| S:144 E:153 ||| RB
,  ||| S:153 E:155 ||| ,
there  ||| S:155 E:161 ||| EX
is  ||| S:161 E:164 ||| VBZ
limited  ||| S:164 E:172 ||| JJ
knowledge  ||| S:172 E:182 ||| NN
of  ||| S:182 E:185 ||| IN
neoplastic  ||| S:185 E:196 ||| JJ
transformation  ||| S:196 E:211 ||| NN
of  ||| S:211 E:214 ||| IN
hepatocytes  ||| S:214 E:226 ||| NN
in  ||| S:226 E:229 ||| IN
HCC ||| S:229 E:232 ||| NNP
.  ||| S:232 E:234 ||| .
In  ||| S:234 E:237 ||| IN
clinical  ||| S:237 E:246 ||| JJ
practice ||| S:246 E:254 ||| NN
,  ||| S:254 E:256 ||| ,
the  ||| S:256 E:260 ||| DT
high  ||| S:260 E:265 ||| JJ
rate  ||| S:265 E:270 ||| NN
of  ||| S:270 E:273 ||| IN
HCC  ||| S:273 E:277 ||| NNP
local  ||| S:277 E:283 ||| JJ
recurrence  ||| S:283 E:294 ||| NN
suggests  ||| S:294 E:303 ||| VBZ
the  ||| S:303 E:307 ||| DT
presence  ||| S:307 E:316 ||| NN
of  ||| S:316 E:319 ||| IN
different  ||| S:319 E:329 ||| JJ
hepatocyte  ||| S:329 E:340 ||| JJ
populations  ||| S:340 E:352 ||| NNS
within  ||| S:352 E:359 ||| IN
the  ||| S:359 E:363 ||| DT
liver  ||| S:363 E:369 ||| NN
and  ||| S:369 E:373 ||| CC
particularly  ||| S:373 E:386 ||| RB
in  ||| S:386 E:389 ||| IN
the  ||| S:389 E:393 ||| DT
tumor  ||| S:393 E:399 ||| NN
proximity ||| S:399 E:408 ||| NN
.  ||| S:408 E:410 ||| .
The  ||| S:410 E:414 ||| DT
present  ||| S:414 E:422 ||| JJ
study  ||| S:422 E:428 ||| NN
investigated  ||| S:428 E:441 ||| VBD
primary  ||| S:441 E:449 ||| JJ
human  ||| S:449 E:455 ||| JJ
hepatocyte  ||| S:455 E:466 ||| JJ
cultures  ||| S:466 E:475 ||| NNS
obtained  ||| S:475 E:484 ||| VBN
from  ||| S:484 E:489 ||| IN
liver  ||| S:489 E:495 ||| JJ
specimens  ||| S:495 E:505 ||| NNS
of  ||| S:505 E:508 ||| IN
patients  ||| S:508 E:517 ||| NNS
affected  ||| S:517 E:526 ||| VBN
by  ||| S:526 E:529 ||| IN
cirrhosis  ||| S:529 E:539 ||| NN
and  ||| S:539 E:543 ||| CC
HCC ||| S:543 E:546 ||| NNP
,  ||| S:546 E:548 ||| ,
their  ||| S:548 E:554 ||| PRP$
proliferation  ||| S:554 E:568 ||| NN
and  ||| S:568 E:572 ||| CC
transformation ||| S:572 E:586 ||| NN
.  ||| S:586 E:588 ||| .
Liver  ||| S:588 E:594 ||| JJ
samples  ||| S:594 E:602 ||| NNS
were  ||| S:602 E:607 ||| VBD
obtained  ||| S:607 E:616 ||| VBN
from  ||| S:616 E:621 ||| IN
seven  ||| S:621 E:627 ||| CD
HCC  ||| S:627 E:631 ||| JJ
cirrhotic  ||| S:631 E:641 ||| JJ
patients  ||| S:641 E:650 ||| NNS
and  ||| S:650 E:654 ||| CC
from  ||| S:654 E:659 ||| IN
three  ||| S:659 E:665 ||| CD
patients  ||| S:665 E:674 ||| NNS
with  ||| S:674 E:679 ||| IN
normal  ||| S:679 E:686 ||| JJ
liver  ||| S:686 E:692 ||| NN
( ||| S:692 E:693 ||| -LRB-
NL ||| S:693 E:695 ||| NNP
) ||| S:695 E:696 ||| -RRB-
.  ||| S:696 E:698 ||| .
Immediately  ||| S:698 E:710 ||| RB
after  ||| S:710 E:716 ||| IN
surgery ||| S:716 E:723 ||| NN
,  ||| S:723 E:725 ||| ,
cell  ||| S:725 E:730 ||| NN
outgrowth  ||| S:730 E:740 ||| NN
and  ||| S:740 E:744 ||| CC
primary  ||| S:744 E:752 ||| JJ
cultures  ||| S:752 E:761 ||| NNS
were  ||| S:761 E:766 ||| VBD
obtained  ||| S:766 E:775 ||| VBN
from  ||| S:775 E:780 ||| IN
the  ||| S:780 E:784 ||| DT
HCC  ||| S:784 E:788 ||| NNP
lesion ||| S:788 E:794 ||| NN
,  ||| S:794 E:796 ||| ,
the  ||| S:796 E:800 ||| DT
cirrhotic  ||| S:800 E:810 ||| JJ
tissue  ||| S:810 E:817 ||| NN
proximal  ||| S:817 E:826 ||| NNS
( ||| S:826 E:827 ||| -LRB-
CP ||| S:827 E:829 ||| NNP
,  ||| S:829 E:831 ||| ,
1-3 cm ||| S:831 E:837 ||| CD
)  ||| S:837 E:839 ||| -RRB-
and  ||| S:839 E:843 ||| CC
distal  ||| S:843 E:850 ||| NNS
( ||| S:850 E:851 ||| -LRB-
CD ||| S:851 E:853 ||| NNP
,  ||| S:853 E:855 ||| ,
> ||| S:855 E:856 ||| CD
5 cm ||| S:856 E:860 ||| CD
)  ||| S:860 E:862 ||| -RRB-
to  ||| S:862 E:865 ||| TO
the  ||| S:865 E:869 ||| DT
margin  ||| S:869 E:876 ||| NN
of  ||| S:876 E:879 ||| IN
the  ||| S:879 E:883 ||| DT
neoplastic  ||| S:883 E:894 ||| JJ
lesion ||| S:894 E:900 ||| NN
,  ||| S:900 E:902 ||| ,
or  ||| S:902 E:905 ||| CC
from  ||| S:905 E:910 ||| IN
NL ||| S:910 E:912 ||| NNP
.  ||| S:912 E:914 ||| .
Cells  ||| S:914 E:920 ||| NNS
were  ||| S:920 E:925 ||| VBD
kept  ||| S:925 E:930 ||| VBN
in  ||| S:930 E:933 ||| IN
culture  ||| S:933 E:941 ||| NN
for  ||| S:941 E:945 ||| IN
16  ||| S:945 E:948 ||| CD
weeks ||| S:948 E:953 ||| NNS
.  ||| S:953 E:955 ||| .
Morphologic  ||| S:955 E:967 ||| JJ
analyses  ||| S:967 E:976 ||| NNS
were  ||| S:976 E:981 ||| VBD
performed  ||| S:981 E:991 ||| VBN
and  ||| S:991 E:995 ||| CC
proliferation  ||| S:995 E:1009 ||| NN
rate  ||| S:1009 E:1014 ||| NN
of  ||| S:1014 E:1017 ||| IN
the  ||| S:1017 E:1021 ||| DT
different  ||| S:1021 E:1031 ||| JJ
cell  ||| S:1031 E:1036 ||| NN
populations  ||| S:1036 E:1048 ||| NNS
compared  ||| S:1048 E:1057 ||| VBN
over  ||| S:1057 E:1062 ||| IN
time ||| S:1062 E:1066 ||| NN
.  ||| S:1066 E:1068 ||| .
Glypican-3 ||| S:1068 E:1078 ||| NNP
,  ||| S:1078 E:1080 ||| ,
Heppar1 ||| S:1080 E:1087 ||| NNP
,  ||| S:1087 E:1089 ||| ,
Arginase1  ||| S:1089 E:1099 ||| NNP
and  ||| S:1099 E:1103 ||| CC
CD-44  ||| S:1103 E:1109 ||| CD
positivity  ||| S:1109 E:1120 ||| NNS
were  ||| S:1120 E:1125 ||| VBD
tested ||| S:1125 E:1131 ||| VBN
.  ||| S:1131 E:1133 ||| .
The  ||| S:1133 E:1137 ||| DT
degree  ||| S:1137 E:1144 ||| NN
of  ||| S:1144 E:1147 ||| IN
invasiveness  ||| S:1147 E:1160 ||| NN
of  ||| S:1160 E:1163 ||| IN
cells  ||| S:1163 E:1169 ||| NNS
acquiring  ||| S:1169 E:1179 ||| VBG
neoplastic  ||| S:1179 E:1190 ||| JJ
characteristics  ||| S:1190 E:1206 ||| NNS
was  ||| S:1206 E:1210 ||| VBD
studied  ||| S:1210 E:1218 ||| VBN
with  ||| S:1218 E:1223 ||| IN
a  ||| S:1223 E:1225 ||| DT
transwell  ||| S:1225 E:1235 ||| JJ
migration  ||| S:1235 E:1245 ||| JJ
assay ||| S:1245 E:1250 ||| NN
.  ||| S:1250 E:1252 ||| .
We  ||| S:1252 E:1255 ||| PRP
observed  ||| S:1255 E:1264 ||| VBD
that  ||| S:1264 E:1269 ||| IN
HCC  ||| S:1269 E:1273 ||| NNP
cells  ||| S:1273 E:1279 ||| NNS
maintained  ||| S:1279 E:1290 ||| VBD
their  ||| S:1290 E:1296 ||| PRP$
morphology  ||| S:1296 E:1307 ||| NN
and  ||| S:1307 E:1311 ||| CC
unmodified  ||| S:1311 E:1322 ||| JJ
neoplastic  ||| S:1322 E:1333 ||| JJ
characteristics  ||| S:1333 E:1349 ||| NNS
when  ||| S:1349 E:1354 ||| WRB
cultured ||| S:1354 E:1362 ||| NNS
.  ||| S:1362 E:1364 ||| .
Cells  ||| S:1364 E:1370 ||| NNS
isolated  ||| S:1370 E:1379 ||| VBN
from  ||| S:1379 E:1384 ||| IN
CP ||| S:1384 E:1386 ||| NNP
,  ||| S:1386 E:1388 ||| ,
showed  ||| S:1388 E:1395 ||| VBD
a  ||| S:1395 E:1397 ||| DT
progressive  ||| S:1397 E:1409 ||| JJ
morphologic  ||| S:1409 E:1421 ||| JJ
transformation  ||| S:1421 E:1436 ||| NN
in  ||| S:1436 E:1439 ||| IN
HCC-like  ||| S:1439 E:1448 ||| JJ
cells  ||| S:1448 E:1454 ||| NNS
accompanied  ||| S:1454 E:1466 ||| VBN
by  ||| S:1466 E:1469 ||| IN
modification  ||| S:1469 E:1482 ||| NN
of  ||| S:1482 E:1485 ||| IN
markers  ||| S:1485 E:1493 ||| JJ
expression  ||| S:1493 E:1504 ||| NN
with  ||| S:1504 E:1509 ||| IN
signs  ||| S:1509 E:1515 ||| NNS
of  ||| S:1515 E:1518 ||| IN
invasiveness ||| S:1518 E:1530 ||| NN
.  ||| S:1530 E:1532 ||| .
Absence  ||| S:1532 E:1540 ||| NN
of  ||| S:1540 E:1543 ||| IN
HCC  ||| S:1543 E:1547 ||| NNP
contamination  ||| S:1547 E:1561 ||| NN
in  ||| S:1561 E:1564 ||| IN
the  ||| S:1564 E:1568 ||| DT
CP  ||| S:1568 E:1571 ||| NNP
isolates  ||| S:1571 E:1580 ||| NN
was  ||| S:1580 E:1584 ||| VBD
confirmed ||| S:1584 E:1593 ||| VBN
.  ||| S:1593 E:1595 ||| .
In  ||| S:1595 E:1598 ||| IN
CD  ||| S:1598 E:1601 ||| NN
samples  ||| S:1601 E:1609 ||| NNS
some  ||| S:1609 E:1614 ||| DT
of  ||| S:1614 E:1617 ||| IN
these  ||| S:1617 E:1623 ||| DT
characteristics  ||| S:1623 E:1639 ||| NNS
were  ||| S:1639 E:1644 ||| VBD
present  ||| S:1644 E:1652 ||| JJ
and  ||| S:1652 E:1656 ||| CC
at  ||| S:1656 E:1659 ||| IN
significantly  ||| S:1659 E:1673 ||| RB
lower  ||| S:1673 E:1679 ||| JJR
levels ||| S:1679 E:1685 ||| NNS
.  ||| S:1685 E:1687 ||| .
With  ||| S:1687 E:1692 ||| IN
the  ||| S:1692 E:1696 ||| DT
present  ||| S:1696 E:1704 ||| JJ
study ||| S:1704 E:1709 ||| NN
,  ||| S:1709 E:1711 ||| ,
we  ||| S:1711 E:1714 ||| PRP
are  ||| S:1714 E:1718 ||| VBP
the  ||| S:1718 E:1722 ||| DT
first  ||| S:1722 E:1728 ||| JJ
to  ||| S:1728 E:1731 ||| TO
have  ||| S:1731 E:1736 ||| VB
identified  ||| S:1736 E:1747 ||| VBN
and  ||| S:1747 E:1751 ||| CC
describe  ||| S:1751 E:1760 ||| VB
the  ||| S:1760 E:1764 ||| DT
existence  ||| S:1764 E:1774 ||| NN
of  ||| S:1774 E:1777 ||| IN
human  ||| S:1777 E:1783 ||| JJ
hepatocytes  ||| S:1783 E:1795 ||| NN
near  ||| S:1795 E:1800 ||| IN
the  ||| S:1800 E:1804 ||| DT
cancerous  ||| S:1804 E:1814 ||| JJ
lesion  ||| S:1814 E:1821 ||| NN
that  ||| S:1821 E:1826 ||| WDT
can  ||| S:1826 E:1830 ||| MD
transform  ||| S:1830 E:1840 ||| VB
in  ||| S:1840 E:1843 ||| IN
HCC  ||| S:1843 E:1847 ||| NNP
in vitro ||| S:1847 E:1855 ||| NNP
.  ||| S:1855 E:1857 ||| .
